Yosuke Asano

Yosuke Asano

Auto-generated profile, based on publicly available information

Yosuke Asano

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHSumie Hiramatsu
Sumie Hiramatsu
KWKatsue S Watanabe
Katsue S Watanabe
SZSonia Zeggar
Sonia Zeggar
YAYosuke Asano
Yosuke Asano
YMYoshia Miyawaki
Yoshia Miyawaki
JWJun Wada
Jun Wada
Global DNA hypomethylation in CD4+ cells in systemic lupus erythematosus (SLE) was suggested to play a key role in the pathogenesis. To identify new methylation-sensitive genes, we integrated genome-wide DNA methylation and mRNA profiling data in CD4+ cells of MRL/lpr (MRL) and C57BL6/J (B6) mice. We identified Cathepsin E (Ctse), in which 13 methyl-CpGs within 583 bp region of intron 1 were hypomethylated, and Ctse mRNA upregulated in MRL compared with B6 mice. One of methyl-CpGs, mCGCG was 93.3 ± 2.05% methylated in B6 mice, while 80.0 ± 6.2% methylated and mutated to CGGG in MRL mice. Kaiso is known to bind to mCGCG and we hypothesized that it represses expression of Ctse in B6 mice. The binding of Kaiso to mCGCG site in B6 mice was reduced in MRL mice revealed by ChIP-PCR. EL4 cells treated with 5-azaC and/or Trichostatin A showed the suppression of binding of Kaiso to mCGCG motif by ChIP-PCR and the overexpression of Ctse was demonstrated by qPCR. Ctse gene silencing by siRNA in EL4 cells resulted in reduction of IL-10 secretion. The hypomethylation of mCGCG motif, reduced recruitment of Kaiso, and increased expression of Ctse and Il-10 in CD4+ cells may be involved in the pathogenesis of SLE.

2 July 2020 in Rheumatology
Verified
Journal Article
Open access
YKYu Katayama
Yu Katayama
YMYoshinori Y; Yoshinori Matsumoto
Yoshinori Y; Yoshinori Matsumoto
YYYuriko Yamamura
Yuriko Yamamura
YAYosuke Asano
Yosuke Asano
KHKeigo Hayashi
Keigo Hayashi
JWJun Wada
Jun Wada

3 September 2018 in Modern Rheumatology Case Reports
Verified
Journal Article
Closed access
YAYosuke Asano
Yosuke Asano
KSKen-Ei Sada
Ken-Ei Sada
KHKeigo Hayashi
Keigo Hayashi
YYYuriko Yamamura
Yuriko Yamamura
SASumie Asano
Sumie Asano
JWJun Wada
Jun Wada
Lymphoproliferative disorders (LPDs) are sometimes found in patients with autoimmune diseases receiving immunosuppressive treatments. However, LPDs in patients with Takayasu arteritis (TAK) were not reported previously. A 41-year-old woman with TAK and ulcerative colitis (UC) maintained remission with 5 mg/day of prednisolone (PSL) and 100 mg/day of azathioprine (AZA). However, the follow up colonoscopy showed reddish, submucosal lesion in the rectum, and histological examination revealed medium-to-large-sized atypical lymphocytes proliferating in the mucosal layer. These lymphoid cells were CD20 positive and Epstein–Barr encoding region (EBER) positive, demonstrating EB virus-associated LPD. After the diagnosis, AZA was discontinued and rituximab (RTX) was initiated for treatment of both LPD and TAK. A follow-up colonoscopy after three months showed no abnormal findings and the remission of both UC and TAK was maintained. As an increased risk of LPD has been reported in patients with inflammatory bowel disease receiving thiopurines, LPD in our case might be related with complication of UC and use of AZA. RTX might be one of the treatment options for cases with TAK complicating other iatrogenic immunodeficiency-associated LPD.

3 June 2025 in Modern Rheumatology
Verified
Journal Article
Closed access
YTYuya Terajima
Yuya Terajima
YMYoshia Miyawaki
Yoshia Miyawaki
KTKoji Takasugi
Koji Takasugi
RHRyozo Harada
Ryozo Harada
WYWataru Yamamoto
Wataru Yamamoto
JWJun Wada
Jun Wada

21 February 2023 in Lupus
Verified
Journal Article
Closed access
YKYu Katayama
Yu Katayama
YMYoshia Miyawaki
Yoshia Miyawaki
KSKenta Shidahara
Kenta Shidahara
SNShoichi Nawachi
Shoichi Nawachi
YAYosuke Asano
Yosuke Asano
JWJun Wada
Jun Wada
Objective: Fatigue is one of the most common complaints and is a potentially modifiable issue in systemic lupus erythematosus (SLE). Studies suggest that alcohol consumption has a protective effect against the development of SLE; however, an association between alcohol consumption and fatigue in patients with SLE has not been studied. Here, we assessed whether alcohol consumption was associated with fatigue using lupus patient-reported outcomes (LupusPRO). Methods: This cross-sectional study, conducted between 2018 and 2019, included 534 patients (median age, 45 years; 87.3% female) from 10 institutions in Japan. The main exposure was alcohol consumption, which was defined as the frequency of drinking [<1 day/month (none group), ≤1 day/week (moderate group), and ≥2 days/week (frequent group)]. The outcome measure was the Pain Vitality domain score in LupusPRO. Multiple regression analysis was performed as the primary analysis after adjusting for confounding factors, such as age, sex, and damage. Subsequently, the same analysis was performed as a sensitivity analysis after multiple imputations (MIs) for missing data ( n = 580). Results: In total, 326 (61.0%) patients were categorized into the none group, 121 (22.7%) into the moderate group, and 87 (16.3%) into the frequent group. The frequent group was independently associated with less fatigue compared with none group [β = 5.98 (95% CI 0.19–11.76), p = 0.04], and the results did not substantially deviate after MI. Conclusions: Frequent drinking was associated with less fatigue, which highlights the need for further longitudinal studies focusing on drinking habits in patients with SLE.